BMO vs CME

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating marginal financial health, and the absence of an Altman Z-Score prevents a full solvency risk assessment. Despite solid profitability metrics like a 38.67% operating margin and strong revenue growth of 15.50%, earnings growth is inconsistent, with recent Q/Q declines and volatile quarterly surprises. The stock trades above its Graham defensive value of $127.87 at $137.69, yet below the analyst target of $127.91, while offering a solid 3.45% dividend yield with a sustainable 56.29% payout ratio. Technical trend sentiment is weak at 10/100, offsetting positive insider sentiment, resulting in a neutral overall stance.

CME Group trades near fair value with strong profitability and a dominant market position in financial derivatives, supported by a 58.95% profit margin and 63.39% operating margin—both well above sector averages. However, near-term revenue contraction (-3.0% YoY) and stagnant earnings growth (0.0% YoY) raise concerns about cyclical headwinds, while the P/E of 27.6x is above the sector average of 21.8x, limiting upside. Price momentum remains solid with a 1Y return of +33.3%, but insider selling and a 103.7% payout ratio signal caution. Analysts are unanimous in a 'hold' rating, aligning with our neutral stance given mixed fundamentals and valuation.